This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.

J-147

Curcumin-derived investigational neuroprotective from the Salk Institute.

Aliases (3)

J147 · Salk J-147 · curcumin analog J-147

TYPICAL DOSE

—

ROUTE

—

CYCLE

—

STORAGE

—

Overview

What is J-147?

Curcumin-derived investigational neuroprotective from the Salk Institute. ATP synthase α-subunit binder. Excellent preclinical story in aged + AD-model mice. Zero human RCTs. Research-chem supply only. Make-the-case-for-it = WATCH-LIST.

What to Expect

Week 1
Tolerability and dose-response.
Week 2-4
Early effect window.
Week 4-8
Peak benefit assessment.
Week 8+
Cycle decision point.

Was this helpful?

Your feedback shapes what we research deeper.

How was your experience with this compound?

Anonymous · one vote per session · results below at 5+ votes.

Loading…

✎

See something off?

Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.

Discussion — click to load ▸

Loading…

Continue: Extended research →

Our verdict, decision matrix, deep dives, controversies, sources

Related compounds

Cross-referenced from J-147

CONFIRMED-IN-USE

Polyphenolic diarylheptanoid (curcuminoid); plant secondary metabolite from Curcuma longa rhizome

Tetrahydrocurcumin

Synthetic angiotensin-IV-derived hexapeptide / oral HGF-c-Met system "potentiator"

7,8-Dihydroxyflavone

Flavonoid / TrkB receptor agonist (small-molecule BDNF mimetic)

Synthetic neurogenic peptide (CNTF-derived adamantylated tetrapeptide derivative)

Synthetic small molecule, hippocampal neurogenic / indirect BDNF modulator (benzylpiperazine-aminopyridine scaffold)